Immunotherapy by ImmunityBio - Cancer Vaccine Research
ImmunityBio’s platforms address the entire immune system, harnessing the power of both innate and adaptive functions of the immune system by activation of ‘first responder’ natural killer (NK) cells, T cells, and macrophages, and establishment of immune memory by dendritic cells.
Immunotherapy Clinical Trials Pipeline - ImmunityBio
Explore ImmunityBio's pipeline to find information on our clinical trials. We have immunotherapy trials in various stages focusing on a variety of diseases.
ImmunityBio Announces FDA Approval of ANKTIVA
2024年4月22日 · FDA approves ImmunityBio's ANKTIVA, a groundbreaking IL-15 receptor agonist for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Learn more today!
Latest News in Targeted Cell Therapies for Cancer ... - ImmunityBio
2024年12月10日 · ImmunityBio’s platform addresses the entire immune system beyond the limitations of chimeric antigen receptor T-cell (CAR-T) therapies and checkpoint inhibitors by activating the natural killer cell, T cells, macrophages, …
Medical Studies & Immunotherapies - Advanced Clinical
ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious disease. Since then we have progressed into a clinical-stage biotechnology company with 27 clinical trials—18 of which are in Phase 2 or 3 development—across 13 indications in liquid and solid tumors.
ImmunityBio Announces $320 Million Investment by Oberland …
2024年1月2日 · ImmunityBio is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that ImmunityBio believes sharply reduce or …
Pharmaceutical Biotechnology & Clinical Research Jobs
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s …
2024年10月24日 · “This trial is important for ImmunityBio as our first clinical study of our CAR-NK, CD19 t-haNK cell line, as well as one of our first studies in liquid tumors,” said Patrick Soon-Shiong, M.D., Executive Chairman, Founder and Global …
Glioblastoma Cancer Clinical Trial - ImmunityBio
4 天之前 · Discover ImmunityBio's glioblastoma research. We're conducting and developing innovative immunotherapy trials and mechanisms to treat this disease.
Immunotherapy and Cell Therapy Platforms - ImmunityBio
ImmunityBio works every day to develop immunotheraphies that deliver better outcomes for cancer patients. Visit our website to learn more about our novel investigational immunotherapy and cell therapy platforms.